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Abstract
Background: Chronic systemic inflammation has been associated with incident dementia, but its association with
age-related cognitive decline is less clear. The acute responses of many inflammatory biomarkers mean they may
provide an unreliable picture of the chronicity of inflammation. Recently, a large-scale epigenome-wide association
study identified DNA methylation correlates of C-reactive protein (CRP)—a widely used acute-phase inflammatory
biomarker. DNA methylation is thought to be relatively stable in the short term, marking it as a potentially useful
signature of exposure.
Methods: We utilise a DNA methylation-based score for CRP and investigate its trajectories with age, and
associations with cognitive ability in comparison with serum CRP and a genetic CRP score in a longitudinal study of
older adults (n = 889) and a large, cross-sectional cohort (n = 7028).
Results: We identified no homogeneous trajectories of serum CRP with age across the cohorts, whereas the
epigenetic CRP score was consistently found to increase with age (standardised β = 0.07 and 0.01) and to do so
more rapidly in males compared to females. Additionally, the epigenetic CRP score had higher test-retest reliability
compared to serum CRP, indicating its enhanced temporal stability. Higher serum CRP was not found to be
associated with poorer cognitive ability (standardised β = − 0.08 and − 0.05); however, a consistent negative
association was identified between cognitive ability and the epigenetic CRP score in both cohorts (standardised β =
− 0.15 and − 0.08).
Conclusions: An epigenetic proxy of CRP may provide a more reliable signature of chronic inflammation, allowing
for more accurate stratification of individuals, and thus clearer inference of associations with incident health
outcomes.
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Background
Cognitive impairment in older age is associated with an
increased risk of morbidity and mortality, and a lower
quality of life [1–3]. Given the generally ageing popula-
tion, and the significant personal and public health bur-
den of age-related cognitive decline, insight into its
determinants and the factors contributing to individual
differences is critical. The strongest known risk factor
for cognitive decline is older age, suggesting a unique
facet of the ageing process is likely implicated.
Epidemiological studies have associated ageing with a
progressive shift to a chronic inflammatory state. This
low-grade, typically sub-acute, elevation of peripheral
pro-inflammatory mediators in the absence of overt in-
fection is strongly associated with the susceptibility to,
and progression of, many age-associated diseases and is
a key risk factor for mortality [4–6]. Accumulating evi-
dence has also implicated chronic inflammation with in-
cident dementia, but the association with pre-morbid
cognitive function is less firmly defined and has gener-
ated considerable debate [7]. Evidence from large, pro-
spective cohort and cross-sectional studies has been
largely mixed, with positive, negative, and null associa-
tions identified between serum inflammatory biomarker
levels and cognitive ability [8–12].
These conflicting findings may be attributed to meth-
odological disparity between studies, including marked
differences in both the ages of participants and type of
cognitive assessment batteries used. However, a key issue
in research utilising inflammatory biomarkers is their typ-
ically phasic responses [4]. C-reactive protein (CRP)—an
acute-phase reactant of hepatic origin—is a widely used
marker of inflammation. However, by definition, the
plasma concentration of acute-phase proteins deviates by
25% or more in inflammatory disorders [13]. In particular,
CRP is subject to swift and considerable shifts in response
to injury or acute infection. Serum levels can rapidly in-
crease up to 1000-fold from baseline, typically resolving to
basal concentrations over a period of 7–12 days [14, 15].
This poses a potential issue when utilising CRP to investi-
gate the association between chronic inflammation and
health outcomes: the biological variability of the bio-
marker may not be stable enough to enable reliable strati-
fication using blood samples from individuals gathered at
a single time point [16].
DNA methylation is a widely studied epigenetic mech-
anism involving the addition of methyl groups to the
DNA molecule, typically at cytosine-phosphate-guanine
(CpG) dinucleotides. These modifications are involved in
the regulation of gene expression and are influenced by
both genetics and the environment [17]. Though DNA
methylation is dynamic across the life-course, the short-
term variability in adults is thought to be relatively
stable, marking it as a potentially useful signature of
exposure [18–20]. Through epigenome-wide association
studies (EWAS), DNA methylation signals at individual
CpG sites have been associated with various health and
lifestyle factors, permitting the creation of methylation-
based phenotypic predictors and signatures [21–24]. Re-
cently, a large-scale EWAS of serum CRP in adults (n =
8863 and 4111 of European and African ancestries, re-
spectively) identified DNA methylation correlates of
chronic low-grade inflammation [25]. Using 7 CpG sites
from this data, an inflammation-related epigenetic risk
score was recently created and applied in a developmen-
tal framework investigating inflammation and child and
adolescent mental health [26].
In a longitudinal study of older adults (the Lothian
Birth Cohort 1936) and a large, cross-sectional cohort
(Generation Scotland), we utilise this inflammation-
related epigenetic score and characterise its relationship
with serum CRP levels, a genetic CRP score, and phys-
ical health and lifestyle traits that have previously been
associated with CRP. We examine the longitudinal dy-
namics of serum CRP and the epigenetic score, estab-
lishing the stability of each over time, and if there are
multiple typical trajectories characterising latent sub-
groups of individuals sharing a common profile. Finally,
we assess the comparative associations of each predictor
with cognitive ability.
Methods
Lothian Birth Cohort 1936
The Lothian Birth Cohort 1936 (LBC1936) is a longitu-
dinal study comprising individuals born in 1936, most of
whom completed the Scottish Mental Survey 1947 aged
around 11 years. Full details on the recruitment and as-
sessment protocols of the study have been described
previously [27, 28]. Briefly, 1091 participants were re-
cruited to the study aged around 70 years. To date, up to
three further waves of testing in older age have been
completed at intervals of around 3 years at mean ages of
73, 76, and 79. At each wave, data has been collected on
a wealth of health outcomes, lifestyle factors, cognition,
and biological measures.
Generation Scotland: the Scottish Family Health Study
Generation Scotland (GS) is a family-based genetic epi-
demiology cohort sampled from the general population
across Scotland. The recruitment protocol and cohort
characteristics are described in detail elsewhere [29, 30].
Initially, 7953 individuals aged between 18 and 65 years
were recruited between 2006 and 2011 from General
Practitioner registries. Family members of these subjects
aged between 18 and 99 years were then approached to
participate. The final cohort comprised around 24,000
subjects. Data were collected on various cognitive,
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psychiatric, and health measures, and DNA samples
were collected for genotyping and methylation profiling.
Phenotype preparation
C-reactive protein
LBC1936 Serum CRP was measured from venesected
whole-blood samples. Levels were quantified using both
a low-sensitivity assay (mg/L) performed using a dry-
slide immuno-rate method on an OrthoFusion 5.1 F.S
analyser (Ortho Clinical Diagnostics). This assay cannot
distinguish values less than 3 mg/L, thus all readings of
< 3 mg/L were assigned a value of 1.5 mg/L [31].
Generation Scotland CRP was quantified at the Univer-
sity of Glasgow using a commercial high-sensitivity assay
on an automated analyser (c311, Roche Diagnostics,
UK). Manufacturer’s calibration and quality control were
employed. CRP data was available for 419 individuals.
These samples had been selected as father/offspring
pairs in a telomere length study.
Cognitive ability
LBC1936 Fluid-type cognitive ability encompasses the
capacity to perform basic information processing and ex-
temporary thinking tasks, rather than those involving ac-
quired knowledge or experience. This cognitive domain
typically exhibits a decline with age. Scores on different
tests of fluid-type cognitive ability are typically highly
correlated, indicative of a latent general cognitive ability
factor. Here, we derived a single general fluid-type cog-
nitive ability score (gf) for each participant from the first
un-rotated principal component of a principal compo-
nents analysis on six of the Wechsler Adult Intelligence
Scale-III tests. These tests assessed four different cogni-
tive domains: letter-number sequencing and digit span
backwards (working memory), digit-symbol coding and
symbol search (processing speed), matrix reasoning
(non-verbal reasoning), and block design (constructional
ability) [32]. This component explained 53% of the vari-
ance across the 6 tests, with individual test loadings ran-
ging from 0.66 to 0.78. Full details on the testing
protocol for the cognitive tests in LBC1936 have been
reported previously [27, 33].
Generation Scotland Similarly to LBC1936, gf was ob-
tained for each participant from the first un-rotated
principal component of a principal components analysis
of three tests of cognitive ability: logical memory, verbal
fluency (executive function), and digit-symbol coding
(processing speed). This component explained 50% of
the variance across the three tests with test loadings ran-
ging from 0.63 to 0.78. Logical memory was assessed
using the Wechsler Memory Scale-III [34]. Verbal flu-
ency and digit symbol-coding were tested using the
Wechsler Adult Intelligence Scale III [32]. Additional in-
formation regarding the cognitive variables in GS has
been described previously [35, 36].
Physical and lifestyle variables
LBC1936 The variables previously associated with CRP
levels included in the analysis in LBC1936 were as fol-
lows: body mass index (BMI: the ratio of weight in kilo-
gram divided by height in square metres), self-reported
smoking status (current smoker, ex-smoker, never
smoker), alcohol consumption in a typical week (units),
and social deprivation. Social deprivation was measured
using the Scottish Index of Multiple Deprivation
(SIMD). The SIMD ranks geographical areas in Scotland
based on current income, employment, health, educa-
tion, skills and training, geographic access to services,
housing, and crime. The SIMD provides a standardised
measure of relative deprivation throughout Scotland.
Generation Scotland The variables in GS were all mea-
sured as described for LBC1936, the only exception be-
ing smoking status in which ex-smokers were divided
into those who had quit within the previous 12months
of their blood sample date and those who had quit prior
to that.
Inflammation-related poly-epigenetic score
Details on the DNA methylation preparation for each
cohort are presented in Additional file 1. An
inflammation-related poly-epigenetic score (DNAm
CRP) was derived for each participant as described by
Barker et al. [26]. Briefly, methylation beta values were
extracted for the 7 CpG sites shown to have the stron-
gest evidence of a functional association with serum
CRP levels. These values were multiplied by their re-
spective regression weights (corresponding to change in
DNA methylation beta values per 1 unit increase in nat-
ural log-transformed CRP) taken from the largest EWAS
of CRP to-date and summed to generate a single DNAm
CRP score for each participant (Additional file 2: Table
S1 [25]). All of the regression weights from the EWAS
were negative, resulting in a higher DNAm CRP score
(i.e. closer to zero) corresponding to a prediction of in-
creased CRP levels. Of the 7 CpG sites included in the
original measure, one was not available on the EPIC
array and was therefore was unavailable in the GS data
(cg06126421). A DNAm CRP score inclusive of the
remaining 6 CpG sites was utilised in analyses for GS.
It should be noted that LBC1936 contributed 296
high-sensitivity CRP samples (from wave 2) to the
EWAS of CRP from which the DNAm SCRP score was
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derived [25]. This may mean results from this cohort are
overfitted; however, the LBC1936 individuals represent a
small subset of the discovery sample (n = 8863), and the
probes were selected to be highly significant so it is un-
likely this had a significant impact on results.
Genetic score for CRP
Information on genotyping for each cohort is presented
in Additional file 1. An additive weighted genetic score
for CRP was constructed in both cohorts from the 18
single nucleotide polymorphisms (SNPs) that passed the
genome-wide threshold (p < 5 × 10−8) in the largest
available genome-wide association study (GWAS) of
CRP to date [23]. Weighted dosages were calculated by
multiplying the dose of each risk allele by the effect esti-
mate from the GWAS (Additional file 2: Table S2). An
imputation quality score of > 0.8 was applied to the
SNPs.
Statistical analysis
Pearson correlations were calculated between serum
CRP, the DNAm CRP score (and its component CpGs),
and the genetic CRP score in each cohort. Inter-wave
correlations and intraclass correlation coefficients were
estimated for the DNAm CRP score and serum CRP
over the four waves of follow-up in LBC1936 to assess
the stability of the measures over time.
Linear mixed models were used to investigate the
change in the DNAm CRP score and serum CRP over
the four waves in LBC1936. Sex was included as a fixed
effect, age (years) as the timescale, and participant ID as
a random effect on the intercept. Latent class mixed
models were used to account for potential population
heterogeneity in the trajectories and to determine the
number of differing trajectories in both the serum and
DNAm CRP data. Initially, a model with a single class
was run. Additional classes were then added (up to 5)
until the optimal number of classes was established
using the Bayes Information Criterion (BIC) and the
mean posterior probability of belonging to each class
(mean probability > 0.65).
To investigate the validity of the DNAm and gen-
etic CRP scores as markers of inflammation, linear re-
gression models were run with phenotypes that have
previously been associated with circulating CRP levels:
BMI [37], smoking [38–40], alcohol [41], and
deprivation [42, 43]. Age and sex have previously
been identified as strong determinants of circulating
CRP levels and thus were included as covariates in
these models. Each phenotype was additionally in-
cluded as a covariate unless fitted as the dependent
variable of interest. Linear regression models were
then used to obtain the cross-sectional associations
between gf and serum CRP, the DNAm CRP score,
and the genetic CRP score. Models were adjusted for
the aforementioned correlated phenotypes. Methyla-
tion set was included as an additional covariate in
GS (see Additional file 1). In LBC1936, models were
conducted at wave 1 (age ~ 70) of the study. To de-
termine which CpG site in the DNAm CRP score was
most relevant to the cognitive association, fully ad-
justed models with each of the CpGs that comprise
the score as independent variables were computed.
Correction for multiple testing was applied using the
false discovery rate (FDR p < 0.05) [44].
Linear mixed effect models, with the baseline
DNAm CRP score or serum CRP included as a fixed
effect interaction with age, were used to test the pre-
diction of subsequent change in cognitive ability. Par-
ticipant ID was fitted as a random effect on the
intercept.
Numeric variables were scaled to have a mean of zero
and a variance of 1. Serum CRP and alcohol intake data
were log-transformed (natural log) prior to analyses due
to positive skews in their distribution.
Statistical analysis was performed in R version 3.5.0
[45]. Linear mixed-effect models and latent class mixed
models were implemented using the ‘lmerTest’ and the
‘lcmm’ package, respectively [46, 47].
Results
Cohort information
Descriptive statistics of all the variables used in analyses
are presented in Table 1. LBC1936 is an older cohort
than GS (LBC1936 wave 1: mean = 69.5 years; GS: mean
= 50.9 years), with a more even balance between sexes
(LBC1936: 49% female; GS: 58% female). LBC1936 had a
higher mean CRP (5.26 mg/L) compared to GS (2.65
mg/L). The mean genetic score for CRP was 2.16 in
LBC1936 and 2.15 in GS.
Correlation between serum CRP, DNAm CRP score, and
genetic score
In both cohorts, the Pearson correlations between the
DNAm CRP score and serum log(CRP) were moderate
(LBC1936: r = 0.34, 95% CI [0.28, 0.4]; GS: r = 0.28
[0.19, 0.36]), with the DNAm CRP score showing a
stronger correlation with serum CRP than any one of its
composite CpGs in both cohorts (Additional file 3. Fig-
ures S1 and S2). In LBC1936, the correlation between
the genetic score for CRP and serum CRP was 0.21
[0.15, 0.27], and in GS, it was 0.29 [0.2, 0.38]. The correl-
ation between the DNAm CRP score and the genetic
score was low in LBC1936 (r = 0.07 [0.06, 0.14]) and not
significantly different to zero in GS (r = − 0.01 [− 0.03,
0.016]).
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Trajectories of the DNAm CRP score and serum CRP
Plots of the observed trajectories of both serum log(CRP)
and the DNAm CRP score in LBC1936 are shown in Fig. 1a.
The observed trajectories of serum CRP in LBC1936 have
been reported previously [48]. log(CRP) was found to decline
over the 9 years of follow-up (β = − 0.014, SE = 0.005, p =
0.003). Conversely, the DNAm CRP score was found to in-
crease by an average of 0.07 SD per year (SE = 0.004, p < 2 ×
10−16). An interaction was identified between age and sex, in-
dicating that the DNAm CRP score inclined faster over time
in males compared to females (β = 0.018, SE = 0.007, p =
0.009). Plots of the pseudo-trajectories of serum log(CRP)
and the DNAm CRP score in GS are shown in Fig. 1c. Both,
log(CRP) and the DNAm CRP score increased with age (β =
0.011, SE = 0.004, p = 0.008; β = 0.013, SE = 0.0008, p < 2 ×
10−16, respectively). Again, an interaction between age and
sex was identified in the DNAm CRP score, with a more
rapid rise in males than females (β = 0.017, SE = 0.002, p = 2
× 10−16).
To further investigate possible population heterogeneity
in the trajectories, latent class analyses were conducted in
LBC1936. The model with two latent classes had the best
fit for serum log(CRP) (Additional file 2: Table S3).
Though the BIC was minimised with four latent classes,
this included a class of only 27 individuals and a low mean
posterior class membership probability for class 1 (65.6%).
The model with three classes also exhibited a low poster-
ior probability of belonging to each latent class for class 2
(61.4%); therefore, the model with two classes was selected
in which the mean probabilities for class membership
were high—0.95 and 0.86 for class 1 and class 2, respect-
ively. The two underlying mean trajectories are presented
in Fig. 1b. In this model, class 1 (n = 811, 75.5%) exhibited
a stable trajectory, with no evident change over the eighth
decade (β = − 0.0025, SE = 0.005, p = 0.96). Class 2 (n =
263, 24.5%) showed a decline over time, likely indicating a
subset of individuals exhibiting regression to the mean (β
= − 0.032, SE = 0.008, p = 1 × 10−4). For the DNAm CRP
score, class determination indicated the model with one
class best fit the data. Here, a small elevation over time
was identified (β = 0.06, SE = 0.005, p < 1 × 10−5).
Stability of the DNAm CRP score and serum CRP
The intraclass correlation coefficient for serum CRP over
the four waves of follow-up in LBC1936 was 0.72 (95%
CI [0.69, 0.74], p < 2 × 10−16). For the DNAm CRP
score, it was 0.82 ([0.75, 0.86], p < 2 × 10−16), ranging
from 0.60 (cg27023597) to 0.94 (cg06126421) in the 7
CpG sites that comprised the score. The correlations of
the DNAm CRP score and serum CRP between each of
the four waves in LBC1936 are presented in Additional
file 3: Figure S3. The inter-wave correlations of serum
log(CRP) ranged from 0.3 (wave 1–wave 4) to 0.45 (wave
1–wave 2). The correlations of the DNAm CRP score
between waves were stronger, ranging from 0.53 (wave
1–wave 4) to 0.75 (wave 2–wave 3), indicating an en-
hanced temporal stability.
Associations with determinants of CRP
The associations between serum CRP, the DNAm CRP
score, and the health and lifestyle phenotypes are pre-
sented in Table 2. No associations were found between
the genetic score and any of the phenotypes in either co-
hort (Additional file 2: Table S4). Higher serum CRP
was found to associate with a higher BMI and smoking
status in both cohorts (LBC1936 BMI: β = 0.27, SE =
0.03, pFDR = 2.1 × 10
−17; smoking: log odds = 0.30, SE =
Table 1 Cohort characteristics
n Mean Median Range SD
LBC1936 wave 1 1091 – – – –
Age (years) – 69.53 69.54 67.61, 71.29 0.83
Sex (% female) 49.8 – – – –
CRP (mg/L) 1054 5.26 3.0 1.5, 90 6.78
DNAm CRP 894 −
0.019
− 0.019 − 0.024, − 0.015 0.0013
Genetic score 1005 2.16 2.16 1.23, 2.83 0.25
gf 1070 0.096 0.12 − 3.43, 3.017 1.0091
BMI (kg/m2) 1083 27.78 27.39 16.023, 48.52 4.36
Alcohol (units/
week)
1063 9.93 6 0, 70 12.12
Smoking status 894 − − − −
Current 102 − − − −
Ex 375 − − − −
Never 417 − − − −
SIMD 1083 5342 5342 4, 6505 1907
Generation Scotland 7028 – –
Age (years) – 50.89 52.75 18, 93.3 12.96
Sex (% female) 58.2 – – – –
CRP (ng/mL) 419 2.65 1.21 0.15, 63.25 5.59
DNAm CRP 7028 −
0.012
− 0.013 − 0.016, −
0.0089
<
0.001
Genetic score 7028 2.15 2.17 1.14, 2.91 0.26
gf 6880 0.0063 0.042 − 4.15, 3.89 0.99
BMI (kg/m2) 6988 26.93 26.15 14.78, 51.29 5.089
Alcohol (units/
week)
6414 10.49 8 0, 73 11.017
Smoking status 6854 – – – –
Current 1135 – – – –
Ex 2167 – – – –
Never 3552 – – – –
SIMD 6693 3953 4456 3, 6505 1857
LBC1936 Lothian Birth Cohort 1936, CRP C-reactive protein, DNAm DNA
methylation, gf general cognitive ability score, SIMD Scottish Index of Multiple
Deprivation, BMI body mass index
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0.07, pFDR = 1.4 × 10
−5; GS BMI: β = 0.29, SE = 0.04,
pFDR = 3.3 × 10
−10; smoking: log odds = 0.26, SE = 0.11,
pFDR = 0.03) but not with alcohol intake or social
deprivation (p ≥ 0.14). In the subset of individuals with
measured CRP in GS, the DNAm CRP score associated
with BMI (β = 0.15, SE = 0.06, pFDR = 0.019) and alcohol
intake (β = 0.19, SE = 0.06, pFDR = 0.003) but not with
smoking (p = 0.29). In LBC1936 and the full GS cohort, a
higher DNAm CRP score robustly associated with a higher
BMI (LBC1936: β = 0.14, SE = 0.04, pFDR = 2.4 × 10
−4; GS:
β = 0.19, SE = 0.01, pFDR = 2.4 × 10
−38), increased alcohol
intake (LBC1936: β = 0.12, SE = 0.03, pFDR = 0.001;
GS: β = 0.15, SE = 0.01, 9.6 × 10−24), a more
deprived socioeconomic status (LBC1936: β = − 0.12,
SE = 0.03, pFDR = 7.2 × 10
−4; GS: β = − 0.07, SE = 0.01,
pFDR = 1.4 × 10
−6), and being a smoker (LBC1936: log
odds = 0.54, SE = 0.07, pFDR = 1.5 × 10
−12; GS: log odds =
0.24, SE = 0.03, pFDR = 1.5 × 10
−18).
Fig. 1 Trajectories of serum CRP and the DNAm CRP score over age. a Observed trajectories in the Lothian Birth Cohort 1936. Grey lines
represent individual participant trajectories with regression lines shown for females and males in blue and purple, respectively. b Latent
trajectories in Lothian Birth Cohort 1936. Latent classes are shown in red (class 1) and blue (class 2). c Pseudo-trajectories in Generation Scotland
for CRP (n = 419) and the DNAm CRP score (n = 7028). Regression lines are as in (a). Black lines represent density. DNAm = DNA methylation;
CRP = C-reactive protein
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Associations with cognitive ability
The associations between the individual predictors—serum
CRP, the DNAm CRP score, and the genetic score—and gf
are presented in Table 3. CRP has previously been found to
associate with cognitive ability cross-sectionally at wave 1
of LBC1936 [49]. In fully adjusted models in LBC1936, nei-
ther serum CRP nor the genetic CRP score was associated
with gf (pFDR ≥ 0.16), but an inverse association was identi-
fied with the DNAm CRP score (β = − 0.08, SE = 0.03, pFDR
= 0.04). Similar results were found in GS, with no associ-
ation with serum CRP or the genetic score (Table 3, pFDR ≥
0.71) but a higher DNAm CRP score associated with poorer
cognitive ability (β = − 0.04, SE = 0.01, pFDR = 0.04). The
association between gf and each of the CpG sites within the
DNAm CRP score is presented in Additional file 2: Table
S5. In both cohorts, cg18181703 (SOCS3) was associated
with gf with a larger effect size than that of the DNAm CRP
score, suggesting this locus is particularly important in driv-
ing the observed cognitive associations.
The longitudinal associations between baseline serum
CRP and DNAm CRP score and gf in LBC1936 are pre-
sented in Additional file 2: Table S6. There was no evi-
dence to suggest either CRP or the DNAm CRP score at
wave 1 of LBC1936 was predictive of subsequent change
in gf over the 4 years of follow-up (p ≥ 0.69).
Discussion
We identified discrepant trajectories of serum CRP with
age across two cohorts, whereas the DNAm CRP score
was invariably found to increase with age and to do so
more rapidly in males than in females. The DNAm CRP
score additionally showed robust associations with
health and lifestyle variables previously found to impact
CRP levels. We found that a higher DNAm CRP score
associated with lower cognitive function; however, nei-
ther baseline serum CRP nor the DNAm CRP score was
associated with longitudinal change in cognitive ability.
Whereas ageing is considered to be linked to systemically
raised inflammation [4], we identified divergent dynamics
of serum CRP in the assessed cohorts, with both increasing
and declining trajectories seen as a function of age. Con-
trastingly, we identified congruous increases in the DNAm
CRP score in relation to age. In LBC1936, the increase per
year was greater than that seen in GS, likely due to the in-
clusion of only older individuals within the cohort who
may be more likely to experience a progressive elevation in
inflammation [4, 50]. Furthermore, we consistently found a
significant interaction between the DNAm CRP score and
sex, with males having a steeper incline compared to fe-
males. This is conceivably due to men having a lower life-
Table 2 Associations between physical and lifestyle traits, and serum CRP and the DNAm CRP score
Lothian Birth Cohort 1936
CRP DNAm CRP
β SE P FDR P β SE P FDR P
BMI 0.27 0.03 3.1 × 10−18 2.1 × 10−17 0.14 0.04 8.1 × 10−5 2.4 × 10−4
Alcohol − 0.004 0.03 0.26 0.41 0.12 0.03 5.9 × 10−4 0.001
SIMD − 0.05 0.03 0.14 0.25 − 0.12 0.03 2.7 × 10−4 7.2 × 10−4
Smoking 0.30 0.07 4.2 × 10−6 1.4 × 10−5 0.54 0.07 2.7 × 10−13 1.5 × 10−12
Generation Scotland
CRP DNAm—subset with measured CRP DNAm—full dataset
β SE P FDR P β SE P FDR P β SE P FDR P
BMI 0.29 0.04 7.2 × 10−11 3.3 × 10−10 0.15 0.06 0.009 0.019 0.19 0.01 8.7 × 10−40 2.4 × 10−38
Alcohol 0.01 0.07 0.83 0.91 0.19 0.06 0.001 0.003 0.15 0.01 7.1 × 10−25 9.6 × 10−24
SIMD 0.03 0.05 0.53 0.64 − 0.04 0.06 0.45 0.64 − 0.07 0.01 3.7 × 10−7 1.4 × 10−6
Smoking 0.26 0.11 0.01 0.03 0.16 0.11 0.17 0.29 0.24 0.03 1.7 × x10−19 1.5 × 10−18
Log odds are presented for smoking. Analysis was run at wave 1 of the Lothian Birth Cohort 1936 (n = 1091). Significant associations are highlighted in bold
SIMD Scottish Index of Multiple Deprivation, BMI body mass index, CRP C-reactive protein, DNAm DNA methylation, SE standard error, FDR false discovery rate
Table 3 Associations between gf and individual predictors
Standardised β SE Raw P FDR P
Lothian Birth Cohort 1936
log(CRP) − 0.033 0.03 0.26 0.41
Genetic score 0.052 0.03 0.08 0.16
DNAm CRP − 0.084 0.03 0.01 0.04
Generation Scotland
log(CRP) − 0.016 0.05 0.74 0.77
Genetic score 0.007 0.01 0.57 0.71
DNAm CRP − 0.035 0.01 0.01 0.04
Significant associations are highlighted in bold. Analysis was run at wave 1 of
LBC1936 (n = 1091)
CRP C-reactive protein, DNAm DNA methylation, SE standard error, FDR false
discovery rate
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expectancy, and thus accelerated immune dysregulation,
captured by the inflammation-related epigenetic score.
Latent class analysis suggested the majority of individ-
uals in LBC1936 exhibited stable dynamics of serum
CRP over the eighth decade, with a slight decline
identified in a smaller subgroup. The decline is likely
due to a regression to the mean and highlights the
acute nature and serum CRP and the challenges of
utilising it as a biomarker of chronic systemic inflam-
mation in studies where it is quantified only once, or
even at multiple time-points with large sampling in-
tervals across the life-course of a longitudinal study.
Contrastingly, the analysis of the DNAm CRP score
indicated a consistent population trajectory that in-
creased over time. Moreover, the DNAm CRP score had
higher inter-wave correlations and test-retest coefficients
and more robust associations with the determinants of
serum CRP, indicating it had less associated error than
phenotypic CRP. As DNAm is considered relatively stable,
the DNAm CRP score could conceivably be regarded as a
cumulative, composite measure of inflammation akin to
the HbA1c test typically utilised in diabetic patients to ob-
tain a ~ 3-month average blood glucose recording [51].
The DNAm CRP score may then have the potential to
provide a more sensitive biomarker of chronic inflamma-
tion, overcoming the noise that the phasic nature of serum
CRP introduces, allowing for more reliable analyses of
chronic inflammatory variance and its associative
relationships.
In both cohorts, we reported an inverse association
between cognitive ability and the DNAm CRP score,
but no association with the genetic score or measured
CRP. It seems this association is largely driven by
cg18181703 (SOCS3). This site has previously been
associated with higher scores on tests of vocabulary
and speed of information processing in an EWAS
meta-analysis of cognitive abilities (LBC1936 contrib-
uted to this study [52]), as well as with type 2 dia-
betes and BMI—both strong correlates of circulating
CRP levels [53, 54]. SOCS3 itself is involved in regu-
lating pro-inflammatory cytokine signalling, and its
expression has been found to be upregulated in the
brains of patients with Alzheimer’s disease, suggesting
it may be an important site in linking peripheral
metabolic and inflammatory processes with central
pathology and function [55]. Our results are consist-
ent with a recent study identifying a negative associ-
ation between the DNAm CRP score at birth and
cognitive function in early life [26]. This, coupled
with our results from GS, whose participant ages span
early-adulthood to later-life, suggests inflammation
and cognition may be related across the life-course
rather than necessarily exclusively in older age. The
larger effect size in LBC1936, however, suggests the
association becomes more pronounced in older adults.
Neither serum CRP nor the DNAm CRP score were
found to associate with longitudinal change in cogni-
tive ability over time indicating no predictive relation-
ship between either measure of inflammation and
cognitive decline. Previous studies have suggested that
inflammation in middle age, rather than later life,
may be a more powerful determinant of age-related
cognitive change, and it would be interesting to utilise
the DNAm CRP score in a longitudinal cohort span-
ning this age range to examine this hypothesis further
[12, 56].
The strengths of this study include the large sample
sizes and the range of longitudinal data available. We
demonstrate that the DNAm CRP score could provide a
proxy measure when CRP itself is not quantified, allow-
ing for the investigation of inflammation in cohorts with
only methylation data available. Limitations include the
typically healthy nature of the two cohorts meaning our
findings may not extrapolate to a more general popula-
tion. Additionally, serum CRP is not directly produced
by immune cells, and thus, it is, in itself, a proxy marker
of inflammation. A chronic signature of inflammation
might also manifest in whole blood through changes in
cell type proportions which should also be considered in
future analyses. While the DNAm CRP score may be cap-
turing a more reliable picture of inflammation than mea-
sured CRP, it would be desirable to investigate its
relationship with a panel of inflammatory mediators and
to create epigenetic scores of other inflammatory bio-
markers to test their comparative performance. Finally, no
causal analysis was conducted in this study, so it remains
to be determined (a) if CRP has a direct effect on methyla-
tion or indeed the opposite is true, though this has begun
to be addressed elsewhere [25, 57]; and (b) if
inflammation-related DNAm is causal of poorer cognition,
vice-versa, or both are influenced by a confounding factor.
Conclusion
Research into the complex relationship between systemic
inflammation and cognitive ability relies upon accurate
characterisation of inflammatory mediators to enable re-
liable conclusions. Here, we show that an inflammation-
related poly-epigenetic score may provide a more stable
index of chronic, low-grade inflammation in comparison
with serum CRP itself. We found the epigenetic score
associated more robustly with cognitive ability compared
to the measured phenotype, demonstrating the potential
value in using epigenetic information in place of labile
phenotypes. DNAm signatures of acute inflammatory
markers may provide a better signature of chronic in-
flammation, allowing for more reliable stratification of
individuals, and thus clearer inference of its association
with incident health outcomes.
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